Skip to main content

Table 1 Patients characteristics

From: Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis

 All patients (n = 121)
Age (years)73 ± 7.3
Body weight (kg)81.0 ± 13.7
Time since diagnosis of prostate cancer (years)7 ± 11
Gleason score at diagnosisa
 < 838 (36%)
 ≥ 869 (64%)
PSA at the time of PET/CT imaging (ng/ml)114 ± 671
Prior lines of systemic treatment
 28 (7%)
 ≥ 3113 (93%)
 ≥ 478 (64%)
 ≥ 544 (36%)
 ≥625 (21%)
Sites of disease on PSMA-PET
 Bone112 (93%)
 Lymph nodes97 (80%)
 Visceralb43 (36%)
 Bone + lymph nodes88 (73%)
 Bone + lymph nodes + visceral34 (28%)
  1. Data are median ± standard deviation or n (%)
  2. PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen
  3. aData missing for 14 patients
  4. bVisceral includes liver, lungs, and adrenal glands